Iván R. González/X
Jan 11, 2025, 11:52
Iván R. González: Trastuzumab-Pertuzumab plus chemotherapy in advanced/metastatic HER2+ breast cancer
Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“EMERALD Study Results: Trastuzumab-Pertuzumab (HP) plus chemotherapy in advanced/metastatic HER2+ breast cancer
Findings:
PFS:
-Eribulin + HP: 14.0 months.
-Taxanes + HP: 12.9 months (HR: 0.95, 95% CI: 0.76–1.19).
-Confirms non-inferiority of eribulin compared to taxanes.
OS:
-Eribulin: Not reached.
-Taxanes: 65.3 months.
Quality of Life: -Longer time to deterioration with eribulin.
Adverse Events:
-Taxanes: More infusion reactions, diarrhea, skin effects, and edema.
-Eribulin: More neutropenia.
Eribulin + HP is a safe and effective first-line treatment option for patients with advanced or metastatic HER2+ breast cancer. ”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 08:14
Jan 15, 2025, 07:53
Jan 15, 2025, 07:27
Jan 15, 2025, 07:22
Jan 15, 2025, 07:07
Jan 15, 2025, 06:56